Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06268886 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease
A Phase 2 study of Alzheimer Disease, Early Onset, sponsored by Bristol-Myers Squibb.
- Active
- Registry status
- Phase 2
- Development phase
- 310
- Enrollment target
- 20
- Study locations
NCT06268886: Active Phase 2 study of Alzheimer Disease, Early Onset, sponsored by Bristol-Myers Squibb.
NCT06268886 is a Phase 2 study of Alzheimer Disease, Early Onset that is active but no longer recruiting, run by Bristol-Myers Squibb. The registered enrollment target is 310 participants, below the 1,460-participant average among 11 other Alzheimer Disease, Early Onset trials with a reported enrollment target (79% lower). The trial reports 20 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06268886, a Phase 2 study of Alzheimer Disease, Early Onset, is active but no longer recruiting, sponsored by Bristol-Myers Squibb.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 310 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the effectiveness, safety, and tolerability of BMS-986446 an Anti-MTBR Tau Monoclonal Antibody in participants with Early Alzheimer's Disease.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG BMS-986446
Study Locations (20)
California
- Local Institution - 0164 - Encino
- Local Institution - 0139 - Fullerton
- Local Institution - 0191 - Irvine
- Local Institution - 0234 - Long Beach
- Local Institution - 0142 - Los Alamitos
- Local Institution - 0037 - Napa
- Local Institution - 0209 - Sacramento
- Local Institution - 0052 - San Francisco
- Local Institution - 0137 - Santa Ana
- Local Institution - 0046 - Sherman Oaks
Arizona
- Local Institution - 0068 - Chandler
- Local Institution - 0102 - Gilbert
- Local Institution - 0019 - Phoenix
- Local Institution - 0018 - Scottsdale
- Local Institution - 0026 - Scottsdale
- Local Institution - 0077 - Tucson
- Local Institution - 0038 - Tucson
Connecticut
- Local Institution - 0106 - Danbury
- Local Institution - 0148 - New Haven
- Local Institution - 0056 - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 310 participants |
| Start Date | 2024-03-20 |
| Est. Completion | 2027-03-18 |
| Phase | Phase 2 |
What the registry record for NCT06268886 still lists
NCT06268886 is an interventional study that assigns participants to a tested intervention. The registered 310 participants enrollment target is mid-sized for trials with a published cap, below the 1,460-participant average among 11 other Alzheimer Disease, Early Onset trials with a reported enrollment target (79% lower).
The record links to 1 condition, with Alzheimer Disease, Early Onset appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06268886 names 20 study sites across 3 states, led by California, Arizona, Connecticut.
Frequently Asked Questions
What is clinical trial NCT06268886 about?
NCT06268886 is a clinical study titled "Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease". The purpose of this study is to assess the effectiveness, safety, and tolerability of BMS-986446 an Anti-MTBR Tau Monoclonal Antibody in participants with Early Alzheimer's Disease.
What is the current status of trial NCT06268886?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 310 participants. The study started on 2024-03-20. Estimated completion is 2027-03-18.
What conditions does trial NCT06268886 study?
This clinical trial studies the following conditions: Alzheimer Disease, Early Onset.
What interventions are being tested in trial NCT06268886?
The interventions under investigation include: Placebo (OTHER), BMS-986446 (DRUG).
Who is sponsoring clinical trial NCT06268886?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06268886 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease, Early Onset
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06268886's enrollment target sits among peer trials
310 4th of 11 higher than 8 of 11 other Alzheimer Disease, Early Onset trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimer Disease, Early Onset trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD) Study
ACTIVE NOT RECRUITING · Phase 2
-
NYSCF Scientific Discovery Biobank
RECRUITING
-
Chronic Treatment of Alzheimer's Disease by Gamma Light and Sound Therapy
RECRUITING · NA
-
Effects of Electrical Stimulation on Verbal Learning in Typical and Atypical Alzheimer's Disease
RECRUITING · NA
-
Lifestyle Interventions for the Treatment of Early Onset Alzheimer's Disease Study
RECRUITING · NA
-
Repurposing Nucleoside Reverse Transcriptase Inhibitors for Treatment of AD
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03039439 · 310 participants
Molecular and Immunohistochemical Profiling of Tumors in Patients With Parathyroid Tumors
- NCT04178018 · 310 participants · NA
Transvaginal Ultrasound and Photoacoustic Imaging of Ovary
- NCT04878094 · 310 participants · Phase 3
A Study of Intra-operative Imaging in Women With Ovarian Cancer
- NCT05459233 · 310 participants · NA
Valve Hemodynamic Optimization Based on Doppler-Echocardiography vs Catheterization Measurements Following ViV TAVR
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI